Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Eyal Meiri"'
1
LEAD BY EXAMPLE: Evaluation of an NCCN and ASCO guideline-based virtual weight loss and healthy lifestyle intervention on providers and staff members at a comprehensive cancer center
Autor: Damien Mikael Hansra, Jacqueline Boodhoo, Anya Warren, Shanetia Avinger, Eyal Meiri
Publikováno v: Journal of Clinical Oncology. 40:e24045-e24045
e24045 Background: Obesity is a leading cause of preventable death in the United States. The incidence of most obesity associated malignancies are increasing. Novel interventions to combat the obesity epidemic are greatly needed. Here we investigate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc1cfc77b4f9c8678d9fccbb80804e9f
https://doi.org/10.1200/jco.2022.40.16_suppl.e24045
Zobrazit plný text záznamu
2
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST)
Autor: Michael C. Heinrich, Robin L. Jones, Margaret von Mehren, Sebastian Bauer, Yoon-Koo Kang, Patrick Schoffski, Ferry Eskens, Olivier Mir, Philippe Cassier, Cesar Serrano, William D. Tap, Jonathan C. Trent, Piotr Rutkowski, Shreyaskumar Patel, Sant P. Chawla, Eyal Meiri, Teresa Zhou, Maria Roche, Suzanne George
Publikováno v: Journal of Clinical Oncology. 38:826-826
826 Background: Targeting oncogenic KIT and PDGFRA mutations revolutionized treatment of patients (pts) with advanced GIST; however, nearly all pts succumb to resistant disease. Avapritinib is a potent and selective kinase inhibitor with broad activi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c7871c1b501cb21a6de8a0f1ad01b45
https://doi.org/10.1200/jco.2020.38.4_suppl.826
Zobrazit plný text záznamu
3
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Autor: Pam K. Mangat, Elizabeth Garrett-Mayer, Olufunlayo Osayameh, Eugene R Ahn, Eyal Meiri, Susan Halabi, Venu Perla, Richard L. Schilsky, Sagun Shrestha
Publikováno v: Journal of Clinical Oncology. 38:133-133
133 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with HTMB treated with P are reported. Met
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1090ab8e649b983eda41e04320b0f37b
https://doi.org/10.1200/jco.2020.38.4_suppl.133
Zobrazit plný text záznamu
4
Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study
Autor: Stacy D. D'Andre, Richard L. Schilsky, Pam K. Mangat, Elizabeth Garrett-Mayer, Sasha L. Warren, Eyal Meiri, Shamika Ranasinghe, Susan Halabi, Sagun Shrestha, Ranju Gupta
Publikováno v: Journal of Clinical Oncology. 38:132-132
132 Background: TAPUR is a phase II basket trial evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with ERBB2 overexpression or amplification
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e5c821f4ddea0ba60641b8dc0fe36a7
https://doi.org/10.1200/jco.2020.38.4_suppl.132
Zobrazit plný text záznamu
5
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST)
Autor: Shreyaskumar Patel, Jonathan C. Trent, Sebastian Bauer, Yoon-Koo Kang, Eyal Meiri, Patrick Schöffski, Margaret von Mehren, Suzanne George, César Serrano, Olivier Mir, Philippe A. Cassier, William D. Tap, Ferry A.L.M. Eskens, Michael Heinrich, Khalid Mamlouk, Piotr Rutkowski, Teresa Zhou, Robin L. Jones, Sant P. Chawla, Maria Roche
Publikováno v: Journal of Clinical Oncology. 37:11022-11022
11022 Background: Targeting oncogenic KIT and PDGFRA mutations revolutionized treatment of patients (pts) with advanced GIST; however, nearly all pts succumb to resistant disease. Avapritinib is a potent and selective kinase inhibitor with broad acti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01db3a0b49c9bd4a68242785436c63d6
https://doi.org/10.1200/jco.2019.37.15_suppl.11022
Zobrazit plný text záznamu
6
Salvage use of Y90 coated hepatic arterial beads in the treatment of liver predominant metastatic colorectal cancer: Cancer Treatment Centers of America Southeastern Region experience
Autor: Charles J. Fulp, Kelly J Manahan, John P. Geisler, John Florin Isac, Eyal Meiri, Henry J. Krebs
Publikováno v: Journal of Clinical Oncology. 36:e15554-e15554
e15554Background: Resin Yttrium-90 hepatic arterial liver directed treatments are commonly used in the treatment of liver predominant metastatic colorectal carcinoma. Although its role in first lin...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e30354f5c0ba93265b47de35462f5b82
https://doi.org/10.1200/jco.2018.36.15_suppl.e15554
Zobrazit plný text záznamu
8
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
Autor: Luigi M. Barbato, Haresh S. Jhangiani, Vickie Baranowski, Eyal Meiri, James J. Vredenburgh, Frederick J. Carter, Hwa-Ming Yang
Publikováno v: Current medical research and opinion. 23(3)
To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study.Patients receiving moderately to highly emetogenic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f1fe3f542f0cda08c13c7be2862414
https://pubmed.ncbi.nlm.nih.gov/17355735
Zobrazit plný text záznamu
9
Identification of MEN1 mutation via next generation sequencing in the Cancer Treatment Centers of America (CTCA) database
Autor: Altovise T. Ewing, Navneet K. Dhillon, Kim Kramer, Eyal Meiri, Giuseppe Del Priore
Publikováno v: Journal of Clinical Oncology. 33:e22083-e22083
e22083 Background: MEN1 is a syndrome associated with increased risk of non-endocrine related malignancies, including breast cancer and lung cancer. We attempted to correlate the MEN1 gene alterati...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb34c81ee0b5be74e9f02e2b9b8c519e
https://doi.org/10.1200/jco.2015.33.15_suppl.e22083
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje